Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
106 people get CEPH articles and Market Currents by email alert.
Get email alerts on CEPH »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
Cephalon Stem Cell Deal Catches Analysts Off-GuardEP Vantage • Sun, Dec 12, 2010 -
-
-
-
-
Regulatory Setback for CephalonZacks Investment Research • Wed, Mar 31, 2010 -
Court, FDA Make for a Bad Day at CephalonEP Vantage • Tue, Mar 30, 2010
-
Why It's Time to Sell CephalonNew Low Observer • Wed, Mar 3, 2010
-
Cephalon Beats and Guides HigherZacks Investment Research • Mon, Feb 15, 2010
-
-
Bulls Betting on CephalonoptionMONSTER • Tue, Dec 29, 2009
-
-
-
Cephalon Chugs Along, Despite Fentora, Provigil SetbacksZacks Investment Research • Tue, Jun 16, 2009
-
SL Pharma Wins SFDA Approval for New Drug and a Clinical TrialChinaBio Today • Fri, Aug 29, 2008 -
The Patent System and the High Price of Cephalon's Arsenic TreatmentDerek Lowe • Tue, Sep 18, 2007 -
Cephalon Reduces Debt LevelsH.S. Ayoub • Thu, Jan 11, 2007 -
Cephalon Plunges on Drug RejectionFredric Cohen, M.D. • Sun, Aug 13, 2006
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
Focus On Billionaire Israel Englander's Top Stock PicksInsider Monkey • Thu, Dec 15, 2011 -
Zweig DiMenna's Top Stock PicksInsider Monkey • Fri, Dec 9, 2011
-
-
-
-
-
-
-
Jim Simons' Defensive Stock PicksInsider Monkey • Fri, Oct 7, 2011
-
20 Biotech Stocks With Strong Corporate GovernanceKapitall • Wed, Oct 5, 2011
-
-
-
5 Highly Shorted Healthcare Stocks Being Sold By Smart MoneyKapitall • Tue, Sep 27, 2011
-
-
-
-
Cephalon's CEO Discusses Q4 2010 Results - Earnings Call TranscriptThu, Feb 10, 2011 • 2 Comments
-
Cephalon Management Discusses Q3 2010 Results - Earnings Call TranscriptFri, Oct 29, 2010
-
Cephalon Q2 2010 Earnings Call TranscriptThu, Jul 29, 2010
-
Cephalon Q1 2010 Earnings Call TranscriptWed, May 5, 2010
-
Cephalon, Inc. Q4 2009 Earnings Call TranscriptFri, Feb 12, 2010
-
Cephalon Q3 2009 Earnings Call TranscriptTue, Oct 27, 2009
-
Cephalon, Inc. Q2 2009 Earnings Call TranscriptTue, Aug 4, 2009
-
Cephalon Inc. Q1 2009 Earnings Call TranscriptTue, May 5, 2009
-
Cephalon, Inc., Q4 2008 Earnings Call TranscriptFri, Feb 13, 2009 • 1 Comment
-
Cephalon Inc. Q3 2008 Earnings Conference Call TranscriptTue, Oct 28, 2008
-
Cephalon, Inc. Q1 2008 Earnings Call TranscriptFri, May 2, 2008
-
Cephalon, Inc. Q4 2007 Earnings Call TranscriptTue, Feb 12, 2008
-
Cephalon Q3 2007 Earnings Call TranscriptThu, Nov 8, 2007
-
Cephalon Q2 2007 Earnings Call TranscriptTue, Jul 31, 2007
-
Cephalon Q1 2007 Earnings Call TranscriptTue, May 1, 2007
-
Cephalon Q4 2006 Earnings Call TranscriptMon, Feb 12, 2007
-
Cephalon Q3 2006 Earnings Call TranscriptFri, Nov 3, 2006
-
Cephalon Q2 2006 Earnings Conference Call Transcript (CEPH)Fri, Aug 4, 2006
-
Cephalon, Inc. Q1 2006 Earnings Conference Call Transcript (CEPH)Wed, May 3, 2006
-
Cephalon Inc. Q4 2005 Earnings Conference Call Transcript (CEPH)Sat, Feb 18, 2006
-
at MarketWatch.com (Oct 14, 2011)
-
at MarketWatch.com (Oct 12, 2011)
-
at MarketWatch.com (Oct 12, 2011)
-
at MarketWatch.com (Oct 11, 2011)
-
at MarketWatch.com (Oct 10, 2011)
-
at MarketWatch.com (Jul 13, 2011)
-
at MarketWatch.com (Jun 14, 2011)
-
at MarketWatch.com (Jun 10, 2011)
-
at CNBC.com (May 18, 2011)
-
at CNBC.com (May 17, 2011)
-
at MarketWatch.com (May 16, 2011)
-
at MarketWatch.com (May 9, 2011)
-
at MarketWatch.com (May 6, 2011)
-
at MarketWatch.com (May 4, 2011)
-
at MarketWatch.com (May 3, 2011)
-
at CNBC.com (May 2, 2011)
-
at CNBC.com (May 2, 2011)
-
at MarketWatch.com (May 2, 2011)
-
at MarketWatch.com (May 2, 2011)
-
at CNBC.com (May 2, 2011)
CEPH vs. ETF Alternatives
Company Description
Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system ("CNS"), pain, oncology and inflammatory disease. In addition to conducting an active... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, March 30, 2011, 10:37 AM Cephalon (CEPH +28.2%) shares continue to trade above Valeant's (VRX +8%) $73/share bid price, a sign that investors expect a higher bid. Valeant says it would consider a higher bid should due diligence warrant it but would "move on" if shareholders prefer. Cephalon's board is reviewing the unsolicited proposal and plans to issue a response during the week of April 4. Comment!
- Tuesday, March 29, 2011, 6:07 PM Valeant Pharmaceuticals (VRX) offers to buy drugmaker Cephalon (CEPH) for ~$5.7B in cash, or $73/share, approx. 29% above its 30-day trading average. VRX +3.6%, CEPH +24.1% AH. (PR) Comment!
- Friday, March 18, 2011, 4:42 PM Power One (PWER) tops Data Explorers' list of short seller bets for the second straight week. The list shows how much of a company’s stock is out on loan, and uses the loan numbers as a proxy for short interest. Rounding out the top 10: GME, JBLU, STN, ANR, CEPH, LCC, CRK, MDP, CLT. Comment!
- Thursday, February 10, 2011, 4:21 PM Cephalon (CEPH): Q4 EPS of $2.19 beats by $0.25. Revenue of $771M (+34% Y/Y) beats by $40M. (PR) Comment! [Earnings]
- Thursday, February 10, 2011, 12:10 AM Notable earnings after Thursday's close: ATHR, CAKE, CEPH, EXPE, IM, KFT, RAX, RSG, TCO, WYNN Comment! [Earnings]
- Wednesday, December 8, 2010, 7:44 AM Cephalon (CEPH) will pay $220M for a 20% stake in Mesoblast (MBLTY.PK) and the right to market the Aussie company’s adult stem-cell therapies for heart and nervous system conditions. Cephalon will pay up to another $1.7B in milestone payments as the therapies move towards commercialization. Comment!
- Thursday, October 28, 2010, 4:26 PM Cephalon (CEPH): Q3 EPS of $2.27 beats by $0.48. Revenue of $717M (+30.5%) vs. $720M. (PR) Comment!
- Thursday, October 28, 2010, 12:10 AM Notable earnings after Thursday's close: ACOM, APKT, ARBA, BKH, BMC, BMRN, CEPH, CERN, CLF, CSTR, CW, DECK, DRC, EGO, EMN, ENH, EXPE, EXR, FII, FSLR, GNW, GPRO, GXP, HIW, HLS, IM, JAH, KLAC, LPS, MCRS, MET, MFE, MSFT, MTW, MTX, MWW, MXIM, NETL, NSR, NUVA, PWER, QSFT, RGC, RMD, ROVI, SBAC, SSNC, SUN, SWI, SWN, THOR, TLEO, USTR, VAR, VPRT, VRSN, VSEA, WR Comment!
- Tuesday, July 27, 2010, 4:34 PM Cephalon (CEPH): Q2 EPS of $2.20 beats by $0.43. Revenue of $727M (+32.7%) vs. $694M. Shares -2.8% AH. (PR) 1 Comment
- Tuesday, July 27, 2010, 12:10 AM Notable earnings after Tuesday's close: ACE, AET, AFL, BRCM, BXP, CBG, CBI, CENX, CEPH, CHRW, DWA, EWBC, FISV, IGT, ILMN, KIM, LVS, MEE, MTW, NBR, NLC, NSC, RFMD, STR Comment!
- Friday, June 4, 2010, 4:55 PM Of all the stocks in the S&P 500, only one - Cephalon (CEPH +0.5%) - posted a gain today. Comment!
- Thursday, May 6, 2010, 2:36 PM If CEOs were paid according to shareholder return, Les Moonves (CBS) would take a $28M pay cut and Eric Schmidt (GOOG) would deserve a $17M raise, according to a model developed by Graef Crystal. Among others who were grossly overpaid: Frank Baldino (CEPH), Randall Stephenson (T), Antonio Perez (EK). Comment!
- Tuesday, May 4, 2010, 4:21 PM Cephalon (CEPH): Q1 EPS of $1.92 beats by $0.36. Revenue of $596M (+14.6%) vs. $586M. Shares +0.3% AH. (PR) Comment!
- Tuesday, May 4, 2010, 12:10 AM Notable earnings after Tuesday's close: ACAS, ATML, BRE, CEPH, CHK, DRH, ESLR, HLS, IDTI, IPI, KGC, MYGN, PXD, SBAC, TE, TIE, UNM, XCO, XL Comment!
- Thursday, February 11, 2010, 4:23 PM Cephalon (CEPH): Q4 EPS of $1.62 beats by $0.04. Revenue of $575M (+6.5%) vs. $573M. Q1 guidance $1.60-$1.70 EPS vs. $1.51 consensus, $575M-$595M revenue vs. $576M consensus. Shares +0.7% AH. (PR) Comment!
- Thursday, February 11, 2010, 12:10 AM Notable earnings after Thursday's close: ACL, BGC, CAKE, CEPH, DCT, MFE, PM, RSG Comment!
-
- View all 0 replies
-
James Stocklasar Thomas Jr.
Cephalon (CEPH) could target Zalicus (ZLCS) on buy-out http://seekingalpha.com/p/3kln - View all 0 replies
-
- View all 0 replies
-
Justin M. Hall
4/7/11 7:40 AM ET: SPPI, CELG, CTIC, AMGN, SNY, CEPH, GSK = Chart Analysis 4/7/11 + Zevalin Update = http://bit.ly/gyV0Om - View all 0 replies
-
- View all 0 replies
-
Wall Street Titan
Athersys (ATHX) CEO purchasing shares. Clinical results due this QTR. Stem cell sector in play with CEPH $2B commitment to Mesoblast. BUY - View all 0 replies
-
Michael Bryant
Valeant Pharmaceuticals International (VRX) is a buy. Good chart. Bidding for CEPH, which will boost its already existing pipeline. - View all 0 replies
-
- View all 0 replies
-
Michael Bryant
Hey, a three-way bid in Cephalon (CEPH), which bid for ChemGenex. Then Valeant bid for CEPH. Does anybody else want to join the bidding? - View all 0 replies
-
Philip Davis
Our call on $CEPH (Cephalon) makes 525% in one week! Congrats to all who played following our FREE post: http://bit.ly/fNkTO5/ - View all 0 replies
LATEST REPLIES